Skip to content
ES
MARKETS / NYSE / HAE
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Haemonetics Corp. HAE

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.3B
▼ 2.0% YoY
$97.3M
▼ 42.0% YoY
$260.4M
▲ 82.8% YoY
In brief

What this company does

Haemonetics offers hospital technologies, plasma collection technologies for plasma centers, and products that enable blood centers to collect blood components. As of March 28, 2026, it employed the full-time equivalent of 3,009 persons, with approximately 78% located in North America and the remaining 22% across 17 other countries. It markets and sells its products in approximately 90 countries through a combination of its own direct sales force and independent distributors in approximately 87 countries. In fiscal 2026, its ten largest customers accounted for approximately 44% of its net revenues. The company manages its business in three principal reporting segments: Plasma, Blood Center and Hospital.

Written from the business description in HAEMONETICS CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 20 May 2026. Every sentence was checked against that document before publication.

Growth
USD 1.3B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.3 · Net income 0.1
0.5B1.0B2008201120142017202020232025
Compound annual growth
+4.5%
+8.9%
+3.9%
+4.6%
−5.5%
+4.1%
+1.3%
−2.9%
+5.8%
+34.2%
+14.1%
+21.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.9% a year over five years — but profit grew slower: net income at +4.1%, earnings per share at +5.8%.

The share count fell from 0.05B to 0.05B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
7 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 11.7% · Net 7.3%
5%10%15%-2%-4%-6%2008201120142017202020232025
ROE
FY2025 · ROE 12.0%
5%10%15%-2%-4%-6%2008201120142017202020232025
Gross margin59.0%
Operating margin11.7%
Net margin7.3%
Return on assets4.0%
EBITDAUSD 217.9M

Each USD of equity produced 12 cents of profit this year.

Cash & shareholders
USD 175.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 260.4
100M200M2008201120142017202020232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 175.0
80M160M-10M-20M2008201120142017202020232025
Dividends paid—
Net buybacksUSD 175.0M
Share of profit179.8%
Consecutive raises—

USD 175.0M in buybacks — 180% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 2.4B
EquityUSD 796.3M
CashUSD 245.4M
Gross debtUSD 1.2B
Net debtUSD 979.1M
Current ratio2.95×

Net debt stands at 123% of equity.

The 18-year record
18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B1.31.41.31.21.00.91.01.00.90.90.90.90.90.90.70.70.60.6
Operating income $B0.20.20.20.20.10.10.10.10.1−0.0−0.00.00.00.10.10.10.10.1
EBITDA $B0.20.30.20.20.10.10.20.20.10.00.00.10.10.10.10.10.1·
Income tax $B0.00.00.00.00.0−0.00.00.00.0−0.00.00.00.00.00.00.00.00.0
Net income $B0.10.20.10.10.00.10.10.10.0−0.0−0.10.00.00.00.10.10.10.1
Free cash flow $B0.30.10.10.10.10.10.10.00.10.10.00.00.10.00.10.10.10.1
EPS, diluted $2.053.312.292.240.841.551.481.040.85−0.51−1.090.320.670.741.301.562.242.27
Dividend / sh $··················
Payout %··················
ROE %12.018.813.214.75.912.112.27.76.1−3.6−7.22.04.45.29.412.510.311.0
Shares out B0.050.050.050.050.050.050.050.050.050.050.050.050.050.050.050.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNYSE
Incorporated inMassachusetts
Fiscal year endsApril 3
Data on record since2008

Share this section

Download image